Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
74.38
-0.59 (-0.79%)
Oct 17, 2025, 12:17 PM EDT - Market open
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $102.66M in the quarter ending June 30, 2025, with 151.54% growth. This brings the company's revenue in the last twelve months to $295.52M, up 254.45% year-over-year. In the year 2024, Tarsus Pharmaceuticals had annual revenue of $182.95M with 948.62% growth.
Revenue (ttm)
$295.52M
Revenue Growth
+254.45%
P/S Ratio
10.09
Revenue / Employee
$914,926
Employees
323
Market Cap
3.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 182.95M | 165.51M | 948.62% |
Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
Dec 31, 2021 | 57.03M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TARS News
- 20 days ago - Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off - Seeking Alpha
- 7 weeks ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Top 2 Health Care Stocks That May Fall Off A Cliff In August - Benzinga
- 2 months ago - Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements - GlobeNewsWire
- 2 months ago - Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - GlobeNewsWire
- 5 months ago - Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off - Seeking Alpha
- 5 months ago - Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown - PRNewsWire